Cancer Antibodies: Competitive Positioning for Success

SUMMARY

Executive Summary

This report aims to analyze the current and future potential of cancer antibodies by examining key fundamentals across the entire pipeline of antibody drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type.

This report is written for you to identify your competition and understand which targeting strategies are at work within antibody drug development. It allows you to pin-point which competitors drugs' clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you.

Drug targets are the critical link between drugs and their role in the treatment of medical disorders. BioSeeker has surveyed the cancer antibody field and identified 145 drug targets belonging to 253 antibodies. This report, Cancer Antibodies: Competitive Positioning for Success, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of cancer antibody drugs.

In the report, BioSeeker reports on 147 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 253 cancer antibody drugs designed for the treatment of 42 different cancer indications. The highest degree of distinctiveness among cancer antibodies is achieved by sorting each of them according to targeted cancer indication and drug target mix. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of cancer antibodies. No less than 165 protein-protein interactions were recognized among and between 98 of the 145 included antibody drug targets.

Why You Should Own Your Own Copy of this Report:

• 260+ pages, with almost a hundred different tables and figures. Includes more than 1,000 active links to drug target related resources on the Internet
• A 253 cancer antibody drugs analysis, under development by 102 investigators, covering 480 developmental projects in cancer
• 145 unique, in-depth, drug target validating profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other antibody drug targets, pursued cancer indications, drugs under development, presence in the Cancer Genome Project etc.
• A unique drug target combination breakdown of cancer antibodies into tumor type and developmental stage
• Unique drug-protein target interactome- and protein-protein of drug targets interactome analysis
• Pathway profiling of cancer antibody drug targets
• Pin-point which competitor drugs' clinical out-come may have bearing on your own drug development
• Who are working on sequels to blockbuster drugs?
• Locate white-spots in the competitive landscape, giving you little or no competition

TABLE OF CONTENTS

• 1 Executive Summary
• 2 About Cancer Highlights
• 3 Methodologies
• 4 Table of Contents
  • 4.1 List of Figures
  • 4.2 List of Tables
• 5 How to Use this Report
• 6 Antibody Target Localization
• 7 The Cancer Genome Project and Antibody Targets
  • 7.1 Antibody Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
• 8 Protein Expression Profiles of Antibody Drug Targets in Human
  • 8.1 Expression in Normal Tissues and Cancer Tissues
  • 8.2 Expression in Human Cancer Cell Lines and Primary Cells
• 9 Pathway Analysis of Antibody Drugs
• 10 Protein-Protein Interactions Among Identified Antibody Targets
• 11 Available Biological Structure Data on Antibody Targets
• 12 Drug Target Profiles of Antibody Targets in Oncology
  • 12.1.1 Auxiliary Transport Protein Activity
  • 12.1.2 Carboxypeptidase Activity
  • 12.1.3 Catalytic Activity
  • 12.1.4 Cell Adhesion Molecule Activity
  • 12.1.5 Chemokine Activity
  • 12.1.6 Cofactor Binding
  • 12.1.7 Complement Activity
  • 12.1.8 Cytokine Activity
  • 12.1.9 DNA Topoisomerase Activity
  • 12.1.10 Extracellular Matrix Structural Constituent
  • 12.1.11 G-Protein Coupled Receptor Activity
  • 12.1.12 Growth Factor Activity
  • 12.1.13 Hormone Activity
  • 12.1.14 Hydrolase Activity
  • 12.1.15 Intracellular Ligand-Gated Ion Channel Activity
  • 12.1.16 Metallopeptidase Activity
  • 12.1.17 MHC Class I Receptor Activity
  • 12.1.18 Molecular Function Unknown
  • 12.1.19 Oxidoreductase Activity
  • 12.1.20 Peptidase Activity
  • 12.1.21 Protease Inhibitor Activity
  • 12.1.22 Protein Binding
  • 12.1.23 Receptor Activity
  • 12.1.24 Receptor Binding
  • 12.1.25 Receptor Signaling Complex Scaffold Activity
  • 12.1.26 RNA-Directed DNA Polymerase Activity
  • 12.1.27 Serine-Type Peptidase Activity
  • 12.1.28 T Cell Receptor Activity
  • 12.1.29 Translation Regulator Activity
  • 12.1.30 Transmembrane Receptor Activity
  • 12.1.31 Transmembrane Receptor Protein Tyrosine Kinase Activity
  • 12.1.32 Unclassified
• 13 The Antibody-Target Interactome
• 14 The Progression and Maturity of Antibody Targets in Oncology: The Preclinical Explosion
  • 14.1 Target Profiles of Cancer Antibodies in Pre-Registration or on the Market
  • 14.2 New Cancer Antibody Targets in Phase III Clinical Development
  • 14.3 New Cancer Antibody Targets in Phase II Clinical Development
  • 14.4 New Cancer Antibody Targets in Phase I Clinical Development
  • 14.5 New Cancer Antibody Targets in Preclinical Development
  • 14.6 Development Profiles of All Identified Cancer Antibody Targets
• 15 Competitive Peer Group Profiling of Antibody Drugs by Cancer Indication
  • 15.1 Biliary Cancer
  • 15.2 Bladder Cancer
  • 15.3 Bone Cancer
  • 15.4 Brain Cancer
  • 15.5 Breast Cancer
  • 15.6 Cervical Cancer
  • 15.7 Colorectal Cancer
  • 15.8 Endometrial Cancer
  • 15.9 Fallopian Tube Cancer
  • 15.10 Gastrointestinal Cancer
    • 15.10.1 Gastrointestinal Stomach Cancer
  • 15.11 Head and Neck Cancer
  • 15.12 Leukemia
    • 15.12.1 Acute Lymphocytic Leukemia
    • 15.12.2 Acute Myelogenous Leukemia
    • 15.12.3 Chronic Lymphocytic Leukemia
    • 15.12.4 Chronic Myelogenous Leukemia
  • 15.13 Liver Cancer
  • 15.14 Lung Cancer
    • 15.14.1 Non-Small Cell Lung Cancer
    • 15.14.2 Small Cell Lung Cancer
  • 15.15 Lymphoma
    • 15.15.1 B-Cell Lymphoma
    • 15.15.2 Hodgkin's Lymphoma
    • 15.15.3 Non-Hodgkin's Lymphoma
    • 15.15.4 T-Cell Lymphoma
  • 15.16 Melanoma
  • 15.17 Mesothelioma
  • 15.18 Myelodysplastic Syndrome
  • 15.19 Myeloma
  • 15.20 Nasopharyngeal Cancer
  • 15.21 Neuroblastoma Cancer
  • 15.22 Oesophageal Cancer
  • 15.23 Ovarian Cancer
  • 15.24 Pancreatic Cancer
  • 15.25 Peritoneal Cancer
  • 15.26 Prostate Cancer
  • 15.27 Renal Cancer
  • 15.28 Sarcoma
  • 15.29 Supportive Care Indications
  • 15.29.1 Chemotherapy-Induced Bone Marrow Injury
  • 15.29.2 Chemotherapy-Induced Anemia
  • 15.30 Thyroid Cancer
• 16 Cancer Antibodies and Their Targets by Companies
  • 16.1 Australia
  • 16.2 Belgium
  • 16.3 Brazil
  • 16.4 Canada
  • 16.5 China
  • 16.6 Cuba
  • 16.7 Denmark
  • 16.8 France
  • 16.9 Germany
  • 16.10 Israel
  • 16.11 Italy
  • 16.12 Japan
  • 16.13 Netherlands
  • 16.14 New Zealand
  • 16.15 Norway
  • 16.16 South Korea
  • 16.17 Sweden
  • 16.18 Switzerland
  • 16.19 United Kingdom
  • 16.20 USA
  • 16.21 Non Industrial Bodies
• 17 Disclaimer
• 18 Drug Index
• 19 Company Index

4.1 List of Figures

• Figure 1: Primary Sub-cellular Localization of Drug Targets
• Figure 2: Visualization of Protein-Protein Interactions Among Antibody Drug Targets
• Figure 3: The Drug-Protein Interactome of Antibody Drugs in Oncology
• Figure 4: Direct Head-to-Head Targeting Interactome of Cancer Antibody Drugs
• Figure 5: Competitive Peer Group Profiling Example

4.2 List of Tables

• Table 1: Primary and Alternate Localization of Antibody Drug Targets
• Table 2: Drug Targets of Cancer Antibodies Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
• Table 3: Available Protein Expression Profiles of Antibody Drug Targets
• Table 4: Pathway Summary
• Table 5: Drug Targets Without any Identified Assigned Pathways
• Table 6: Pathway Profile According to BioCarta of Cancer Antibody Drug Targets
• Table 7: Pathway Profile According to KEGG of Cancer Antibody Drug Targets
• Table 8: Cancer Antibodies Targeting Major Singaling Pathways
• Table 9: Protein-Protein Interactions Among Antibody Drug Targets
• Table 10: Number of Available Biological Structures of Cancer Antibody Targets
• Table 11: Overview of Drug Target Profile Themes
• Table 12: Antibody-Protein Interactome Clusters
• Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, Developmental Projects, and the Presence of New Drug Target Mixes by Developmental Stage
• Table 14: Top 5 Pursued Cancer Antibody Targets
• Table 15: Target Profiles of Cancer Antibodies in Pre-Registration or on the Market
• Table 16: New Cancer Antibody Targets in Phase III Clinical Development
• Table 17: New Cancer Antibody Targets in Phase II Clinical Development
• Table 18 New Cancer Antibody Targets in Phase I Clinical Development
• Table 19: New Cancer Antibody Targets in Preclinical Development
• Table 20: The Progression, Maturity and Competitive Comparison of Antibody Drug Targets in Development
• Table 21: Number of Cancer Antibody Drug Target Mixes Reported by Cancer Indication
• Table 22: Step 1 - Indication Profile of Peer Drugs
• Table 23: Step 2 - All Peer Drugs with Known Cancer Indications
• Table 24: Step 3 - Submarine Peer Drugs
• Table 25: Step 4 -Target Overlap Drugs to Peer Drugs
• Table 26: Drug Targets of Antibodies for the Treatment of Biliary Cancer According to Developmental Stage of Antibody
• Table 27: Drug Targets of Antibodies for the Treatment of Bladder Cancer According to Developmental Stage of Antibody
• Table 28: Drug Targets of Antibodies for the Treatment of Bone Cancer According to Developmental Stage of Antibody
• Table 29: Drug Targets of Antibodies for the Treatment of Brain Cancer According to Developmental Stage of Antibody
• Table 30: Drug Targets of Antibodies for the Treatment of Breast Cancer According to Developmental Stage of Antibody
• Table 31: Drug Targets of Antibodies for the Treatment of Cervical Cancer According to Developmental Stage of Antibody
• Table 32: Drug Targets of Antibodies for the Treatment of Colorectal Cancer According to Developmental Stage of Antibody
• Table 33: Drug Targets of Antibodies for the Treatment of Endometrial Cancer According to Developmental Stage of Antibody
• Table 34: Drug Targets of Antibodies for the Treatment of Fallopian Tube Cancer According to Developmental Stage of Antibody
• Table 53: Drug Targets of Antibodies for the Treatment of Mesothelioma According to Developmental Stage of Antibody
• Table 54: Drug Targets of Antibodies for the Treatment of Myelodysplastic Syndrome According to Developmental Stage of Antibody
• Table 55: Drug Targets of Antibodies for the Treatment of Myeloma According to Developmental Stage of Antibody
• Table 56: Drug Targets of Antibodies for the Treatment of Nasopharyngeal Cancer According to Developmental Stage of Antibody
• Table 57: Drug Targets of Antibodies for the Treatment of Neuroblastoma Cancer According to Developmental Stage of Antibody
• Table 58: Drug Targets of Antibodies for the Treatment of Oesophageal Cancer According to Developmental Stage of Antibody
• Table 59: Drug Targets of Antibodies for the Treatment of Ovarian Cancer According to Developmental Stage of Antibody
• Table 60: Drug Targets of Antibodies for the Treatment of Pancreatic Cancer According to Developmental Stage of Antibody
• Table 61: Drug Targets of Antibodies for the Treatment of Peritoneal Cancer According to Developmental Stage of Antibody
• Table 62: Drug Targets of Antibodies for the Treatment of Prostate Cancer According to Developmental Stage of Antibody
• Table 63: Drug Targets of Antibodies for the Treatment of Renal Cancer According to Developmental Stage of Antibody
• Table 64: Drug Targets of Antibodies for the Treatment of Sarcoma According to Developmental Stage of Antibody
• Table 65: Drug Targets of Antibodies for the Treatment of Chemotherapy-Induced Bone Marrow Injury According to Developmental Stage of Antibody
• Table 66: Drug Targets of Antibodies for the Treatment of Chemotherapy-Induced Anemia According to Developmental Stage of Antibody
• Table 67: Drug Targets of Antibodies for the Treatment of Thyroid Cancer According to Developmental Stage of Antibody
• Table 68: Antibodies with Drug Target Mix and Developmental Projects by Companies in Australia
• Table 69: Antibodies with Drug Target Mix and Developmental Projects by Companies in Belgium
• Table 70: Antibodies with Drug Target Mix and Developmental Projects by Companies in Brazil
• Table 71: Antibodies with Drug Target Mix and Developmental Projects by Companies in Canada
• Table 72: Antibodies with Drug Target Mix and Developmental Projects by Companies in China
• Table 73: Antibodies with Drug Target Mix and Developmental Projects by Companies in Cuba
• Table 74: Antibodies with Drug Target Mix and Developmental Projects by Companies in Denmark
• Table 75: Antibodies with Drug Target Mix and Developmental Projects by Companies in France
• Table 76: Antibodies with Drug Target Mix and Developmental Projects by Companies in Germany
• Table 77: Antibodies with Drug Target Mix and Developmental Projects by Companies in Israel
• Table 78: Antibodies with Drug Target Mix and Developmental Projects by Companies in Italy
• Table 79: Antibodies with Drug Target Mix and Developmental Projects by Companies in Japan
• Table 80: Antibodies with Drug Target Mix and Developmental Projects by Companies in the Netherlands
• Table 81: Antibodies with Drug Target Mix and Developmental Projects by Companies in New Zealand
• Table 82: Antibodies with Drug Target Mix and Developmental Projects by Companies in Norway
• Table 83: Antibodies with Drug Target Mix and Developmental Projects by Companies in South Korea
• Table 84: Antibodies with Drug Target Mix and Developmental Projects by Companies in Sweden
• Table 85: Antibodies with Drug Target Mix and Developmental Projects by Companies in Switzerland
• Table 86: Antibodies with Drug Target Mix and Developmental Projects by Companies in United Kingdom
• Table 87: Antibodies with Drug Target Mix and Developmental Projects by Companies in the USA
• Table 88: Antibodies with Drug Target Mix and Developmental Projects by Non-Industrial Bodies